Invega: prolonged-release paliperidone for schizophrenia

摘要

Paliperidone (Invega) is a new atypical antipsychotic available as modified-release tablets for once-daily administration. Here, Steve Chaplin presents the clinical data relating to its efficacy and adverse affects, and Dr Martin Livingston comments on its place in the treatment of schizophrenia.